NEK7 Degradation Reaches Human Pharmacodynamic Proof

Company Monte Rosa Therapeutics Event Type Clinical Data / Phase 1 Readout Modality Oral Molecular Glue Degrader Asset MRT-8102 Target NEK7 Disease Area Atherosclerotic Cardiovascular Risk (Residual Inflammation) Summary Monte Rosa reported randomized Phase 1 GFORCE-1 data in 108 obese adults with elevated cardiovascular risk.…

🔒

Continue reading this signal

Create a free InSilens account to unlock full articles, analysis, and deal context.

Create Free Account
Tags
Share this article :

Leave a Reply

Your email address will not be published. Required fields are marked *

Saturday Rounds

GSK Acquires Nuvalent for $10.6B
Curium Agrees to Acquire Lantheus for Up to $8 Billion
Typewriter Launches with $56 Million for All-RNA Gene Insertion
Ligand Funds AvenCell CAR T Pipeline